← Leaderboards
Thomas R Fuerst
Univ Of Maryland, College Park
$2,156,141
Attributed
$12,138,284
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,138,284 · 3
By mechanism
R01$11,715,835 · 2
R21$422,449 · 1
Top collaborators
- Brian G. Pierce12 shared
- Alexander Andrianov10 shared
- Roy A Mariuzza10 shared
- Steven Foung5 shared
- Gilad A Ofek5 shared
- Alexander Ploss5 shared
- Nevil John Singh5 shared
- Eric A Toth2 shared
Most similar at Univ Of Maryland, College Park
Same institution · by research overlap
- Brian G. Pierce$5,043,672
- Alexander Andrianov$2,015,325
- Gilad A Ofek$1,245,217
- Siba K Samal$1,024,194
- George A. Belov$4,227,596
Others in their field
Other Emerging Leaders on “Antigens”
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,191,190
- Bala Raja · Luminostics, Inc.$28,624,460
- Hanjoon Ryu$28,519,898
- Thomas Denny · Duke University$22,999,550
- Jay Evans · University Of Montana$22,565,626
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
AntigensVirus EnvelopeLiver DiseasesGlycoproteinsAntibodiesHepatitis C VaccineImmunologicsNeutralizing AntibodyEpitopesVariantBindingViralInterdisciplinary ApproachHepatitis CStructureMolecular ConformationVaccine DevelopmentHepatitis C VirusImmunogenicityCd81 GeneScaffoldImmune ResponseDesignVaccines
Grant awards (12)
Rational design and efficacy testing of vaccines against HCV$1,357,012
R01 · FY2025 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,410,043
R01 · FY2024 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$179,958
R01 · FY2024 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,379,680
R01 · FY2023 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,410,544
R01 · FY2022 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,120,994
R01 · FY2021 · AI · contact PI
Design of immunologically intact soluble HCV E1E2 complexes using transmembrane-mimic scaffolds$230,519
R21 · FY2021 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,128,779
R01 · FY2020 · AI · contact PI
Design of immunologically intact soluble HCV E1E2 complexes using transmembrane-mimic scaffolds$191,930
R21 · FY2020 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,136,335
R01 · FY2019 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,142,860
R01 · FY2018 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,449,630
R01 · FY2017 · AI · contact PI